SCHEMBL324955

SCHEMBL324955

CCCCCc1cn[nH]c1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 4/20 0.41
CYP3A4 P08684 3/20 0.41
TYR P14679 2/20 0.41
TP53 P04637 2/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HCAR2 Q8TDS4 2/20 0.40
HCAR3 P49019 1/20 0.40
PTGS2 P35354 6/20 0.38
LIPG Q9Y5X9 1/20 0.38
ESR1 P03372 2/20 0.37
ADRA2A P08913 2/20 0.37
ADORA3 P0DMS8 2/20 0.37
TACR2 P21452 2/20 0.37
SLC6A2 P23975 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1578080 0.78 HRH3 (0.37) ALOX5CYP3A4TYRTP53MEN1
SCHEMBL17591101 0.78 CYP3A4 (0.39) ALOX5CYP3A4TYRTP53MEN1
SCHEMBL3261204 0.77 TLR8 (0.39) MEN1MAPTKMT2ATDP1LIPG
SCHEMBL11765109 0.77 HRH3 (0.40) MAPTALOX15TDP1HCAR2HCAR3
SCHEMBL12235362 0.73 ALDH1A1 (0.43) TP53MEN1MAPTALOX15TSHR
SCHEMBL8235993 0.72 HRH3 (0.42) CYP3A4ALOX15ADORA3ADORA2A
SCHEMBL31287983 0.72 HCAR2 (0.41) ALOX5CYP3A4TYRTP53MEN1
SCHEMBL4372160 0.72 PARP1 (0.38) MAPTALOX15HCAR2HCAR3ALDH1A1
SCHEMBL17224796 0.68 KDM4E (0.49) HCAR2HCAR3KDM4EALDH1A1HSD17B10
SCHEMBL3399692 0.67 NOS1 (0.46) ALOX5CYP3A4MEN1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217131-B2 Method for extracting a metal particulate from an aqueous solution using a sol-gel derived sorbent ABS MATERIALS, INC. (US) 2012-07-10 US claimed
WO-2011162836-A1 METHOD FOR EXTRACTING A METAL PARTICULATE FROM AN AQUEOUS SOLUTION USING A SOL-GEL DERIVED SORBENT ABS MATERIALS, INC (US) 2011-12-29 WO claimed
US-20110132845-A1 METHOD FOR EXTRACTING A METAL PARTICULATE FROM AN AQUEOUS SOLUTION USING A SOL-GEL DERIVED SORBENT AQUANEX TECHNOLOGIES, LLC 2011-06-09 US claimed
US-8217131-B2 Method for extracting a metal particulate from an aqueous solution using a sol-gel derived sorbent ABS MATERIALS, INC. (US) 2012-07-10 US disclosed
US-8093251-B2 Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-01-10 US disclosed
WO-2011162836-A1 METHOD FOR EXTRACTING A METAL PARTICULATE FROM AN AQUEOUS SOLUTION USING A SOL-GEL DERIVED SORBENT ABS MATERIALS, INC (US) 2011-12-29 WO disclosed
US-8026368-B2 Hydrazide compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2011-09-27 US disclosed
US-20110132845-A1 METHOD FOR EXTRACTING A METAL PARTICULATE FROM AN AQUEOUS SOLUTION USING A SOL-GEL DERIVED SORBENT AQUANEX TECHNOLOGIES, LLC 2011-06-09 US disclosed
US-20090253751-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-10-08 US disclosed
US-20090198060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-08-06 US disclosed
EP-2025671-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2009-02-18 EP disclosed
EP-1947101-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2008-07-23 EP disclosed
US-4036812-A ULTRAVIOLET STABILIZERS FOR POLYMERS SANDOZ LTD. (CH) 1977-07-19 US disclosed
US-3959265-A NICKEL COMPLEXES; ULTRAVIOLET STABILIZERS SANDOZ LTD. (CH) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090198060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, MPL, IL1RN ALOX5 2074/4885CYP3A4 2936/4885TYR 723/4885
US-20090253751-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, THPO, PTAFR ALOX5 2786/4885CYP3A4 2183/4885TYR 871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.